Performance Enhancing Drugs Market is Increasing at a Healthy CAGR of 4.8% During Forecast to 2023
MRFR has published research on “Performance
Enhancing Drugs Market 2023”
Market Analysis:
The global performance enhancing drugs market is predicted to grow
at a 4.8% CAGR over the forecast period (2017-2023), as per the latest Market
Research Future (MRFR) report. Performance enhancing drugs, simply put, are
different substances, procedures, or chemical agents that are designed to offer
advantages during athletic performance. These drugs affect the body in various
ways, such as increasing the oxygen-carrying capacity of the blood and also
enlarge muscles. Performance enhancing drugs helps the body in recovering from
workouts quickly. This drug can be taken as a topical treatment, injection, or
a pill.
Various factors are propelling the performance enhancing drugs
market growth. These factors, as stated by the MRFR report, include rising use
of anabolic steroids to treat various medical conditions such as anemia, pain
management, and certain types of breast cancer, availability of huge funds for
research and development activities, and various benefits for athletes such as
muscle enlargement and increased blood’s oxygen carrying capacity.
On the contrary, the use of performance enhancing drugs leads to numerous
side effects such as heart attack and masculinization and heart attack in
females, and diminished sperm production and acne in males. This may impact the
performance enhancing drugs market growth over the forecast period.
Key Players:
Eli Lilly and Company. (US), Onnit
Labs, LLC. (US), Douglas Laboratories. (US), BrainAlert, LLC (US), Novo Nordisk
A/S (Europe), AstraZeneca (Europe), Bayer AG (Europe), Balkan Pharmaceuticals
(Europe), and Taj Pharmaceuticals Limited (India
Market Segmentation:
The Market Research Future report provides a wide segmental
analysis of the Performance
Enhancing Drugs Market based on products, types, and end users.
Based on types, the performance enhancing drugs market is
segmented into nootropic, ergogenic aids, and others. The ergogenic aids
segment is again segmented into human growth hormone, dehydroepiandrosterone
(DHEA), anabolic steroids, and others. The nootropic segment is further
segmented into choline and acetylcholine intermediates, ampakines, racetams,
and others.
Based on products, the performance enhancing drugs market is
segmented into patches, injections, pills, and others.
Based on end users, the performance enhancing drugs market is
segmented into militaries, students, bodybuilders, athletes, and others.
Regional Analysis:
Based on the region, the performance enhancing drugs market report
covers the latest trends and growth opportunities across Europe, the Americas,
the Asia Pacific (APAC), and the Middle East and Africa. Of these, the Americas
will dominate the market over the forecast period. This is owing to the
presence of well-developed economies having high per capita income, especially in
Canada and the US, the two major contributors of the region. Moreover, the
rising prevalence of breast cancer incidences is likely to push market growth
as anabolic steroids is used for treating various forms of breast cancer.
The performance enhancing drugs market in Europe is predicted to
have the second-largest share in the market over the forecast period. This is
owing to rising acceptance of performance-enhancing drugs in the region and
accessibility of funds for R&D activities.
The performance enhancing drugs market in the APAC region is
predicted to grow at the fastest pace over the forecast period. This is owing
to the presence of immense opportunity in the market, continuously developing
economies, and rising awareness about performance enhancing drugs. Moreover,
immense growth opportunities in this region, the presence of constantly
developing economies, and increasing awareness regarding fitness are also
boosting the market growth.
Browse
More Details @ https://www.marketresearchfuture.com/sample_request/4695
The performance enhancing drugs market in the Middle East and
Africa is predicted to have the least share in the market over the forecast
period. This is owing to the presence of a poor economy in the African region.
A major part of the market share is held by the Middle East, owing to huge
healthcare expenditure and a well-developed healthcare sector.
Related Infographics Reports:
Influenza Diagnostics Market Research Report - Global Forecast till
2023
https://www.marketresearchfuture.com/infographics/influenza-diagnostics-market
Immunoassays in R&D Market Research Report - Global Forecast
till 2023
https://www.marketresearchfuture.com/infographics/immunoassay-in-r-d-market
Comments
Post a Comment